TrialDiabetes, obesity & metabolism2015

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

G H Daniels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.